Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PNMT | P11086 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9407936 | 0.91 | OPRM1 (0.41) | OPRM1OPRK1OPRL1HTR2AMMP2 | |
| SCHEMBL31504306 | 0.89 | HTR2A (0.41) | OPRM1OPRK1OPRL1HTR2AMMP2 | |
| SCHEMBL31504290 | 0.81 | HTR2A (0.38) | OPRM1OPRK1OPRL1HTR2AMMP2 | |
| SCHEMBL1071202 | 0.77 | HTR2A (0.41) | OPRM1OPRK1OPRL1HTR2AMMP2 | |
| SCHEMBL15995119 | 0.73 | OPRM1 (0.42) | OPRM1OPRK1OPRL1HTR2AMAOA | |
| SCHEMBL21312268 | 0.73 | OPRM1 (0.42) | OPRM1OPRK1OPRL1HTR2AMAOA | |
| SCHEMBL15995122 | 0.73 | OPRM1 (0.42) | OPRM1OPRK1OPRL1HTR2AMAOA | |
| SCHEMBL22444908 | 0.72 | OPRM1 (0.38) | OPRM1OPRK1OPRL1HTR2AMMP2 | |
| SCHEMBL22444801 | 0.72 | OPRM1 (0.38) | OPRM1OPRK1OPRL1HTR2AMMP2 | |
| SCHEMBL22444802 | 0.72 | OPRM1 (0.38) | OPRM1OPRK1OPRL1HTR2AMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040122270-A1 | In-situ polymerization of monoethylenically unsaturated monomers with secondary amines | BAYER AKTIENGESELLSCHAFT (DE) | 2004-06-24 | — | — | US | disclosed |
| EP-1428838-A1 | In situ-polymerization of monoethylenically unsaturated monomers with secondary amines | Bayer MaterialScience AG (DE) | 2004-06-16 | — | — | EP | disclosed |
| EP-1428839-A1 | In-situ polymerization of monoethylenically unsaturated monomers with secondary amines | Bayer MaterialScience AG (DE) | 2004-06-16 | — | — | EP | disclosed |
| US-6686424-B2 | USE IN RADICAL POLYMERIZATION; REACTING AN OXIDIZING AGENT WITH A STERICALLY HINDERED SECONDARY AMINE TO PRODUCE A NITROXY RADICAL; ADDING TO THE NITROXY RADICAL ONE OR MORE VINYL MONOMER | BAYER AKTIENGESELLSCHAFT (DE) | 2004-02-03 | — | — | US | disclosed |
| EP-1375457-A1 | One-pot process for the preparation of functionalized alkoxyamines | Bayer Aktiengesellschaft (DE) | 2004-01-02 | — | — | EP | disclosed |
| EP-1375476-A1 | A new process for the synthesis of alkoxyamines active in controlled radical polymerization | Bayer Aktiengesellschaft (DE) | 2004-01-02 | — | — | EP | disclosed |
| US-20040002606-A1 | Process for the synthesis for alkoxy amines and their use in controlled radical polymerization | BAYER AKTIENGESELLSCHAFT (DE) | 2004-01-01 | — | — | US | disclosed |
| US-20030236368-A1 | PREPARATION OF FUNCTIONALIZED ALKOXYAMINE INITIATOR AND ITS USE | BAYER AKTIENGESELLSCHAFT (DE) | 2003-12-25 | — | — | US | disclosed |
| EP-0876413-A1 | POLYMERS SUITABLE AS DISPERSING RESINS | BASF AKTIENGESELLSCHAFT (DE) | 1998-11-11 | — | — | EP | disclosed |
| WO-1997027232-A1 | POLYMERS SUITABLE AS DISPERSING RESINS | BASF AKTIENGESELLSCHAFT (DE) | 1997-07-31 | — | — | WO | disclosed |
| WO-1997027582-A1 | MAGNETIC RECORDING MEDIUM | EMTEC MAGNETICS GMBH (DE) | 1997-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236368-A1 | PREPARATION OF FUNCTIONALIZED ALKOXYAMINE INITIATOR AND ITS USE | NOS1, NOS2, CBR1 | OPRM1 93/4885OPRK1 255/4885OPRL1 478/4885 |
| US-20040002606-A1 | Process for the synthesis for alkoxy amines and their use in controlled radical polymerization | ALKBH3, MAOB, ALKBH1 | OPRM1 91/4885OPRK1 259/4885OPRL1 666/4885 |
| US-20040122270-A1 | In-situ polymerization of monoethylenically unsaturated monomers with secondary amines | ALOX5, PARG, FASN | OPRM1 107/4885OPRK1 615/4885OPRL1 1185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.